Prediction of off-Treatment Response to Lamivudine by Serum Hepatitis B Surface Antigen Quantification in Hepatitis B E Antigen-Negative Patients

Abstract

Background

The timing of antiviral therapy cessation in hepatitis B e antigen (HBeAg)-negative patients is controversial. Here, we aimed to investigate the role of HBV DNA and hepatitis B surface antigen (HBsAg) monitoring to predict off-treatment sustained response.

Methods

A total of 53 HBeAg-negative chronic hepatitis B patients who received lamivudine for 34 ±23 (range 12–76) months and had lamivudine stopped for 47 ±35 months were studied. Primary outcome was sustained response, defined as HBV DNA≤200 IU/ml, at 12 months post-treatment (SR-12).

Results

A total of 9 (17%) patients achieved SR-12. HBV DNA at baseline, month 6 and end of treatment had no association with SR-12. HBsAg levels tended to decrease more significantly during treatment among SR-12 responders. At the end of treatment, both HBsAg ≤2 log IU/ml and reduction by >1 log from baseline had sensitivity, specificity, positive and negative predictive values for SR-12 of 78%, 96%, 78% and 96%, respectively. All 5 patients with HBsAg≤2 log IU/ml and reduction >1 log at the end of treatment achieved SR-12 and all 40 patients with HBsAg>2 log IU/ml and reduction ≤1 log did not have SR-12. The cumulative probability of sustained response and HBsAg clearance at 5 years among patients with HBsAg≤2 log IU/ml were 88% and 72%, respectively, that among patients with HBsAg reduction >1 log were 74% and 61%, respectively.

Conclusions

Monitoring of HBsAg level can guide the timing of stopping lamivudine in HBeAg-negative chronic hepatitis B.

References

Chan

H.L.

, Sung

J.J.

Hepatocellular carcinoma and hepatitis B virus. Semin Liver Dis 2006; 26: 153–161.

Chan

H.L.

, Wong

G.L.

, Wong

V.W.

A review of the natural history of chronic hepatitis B in the era of transient elastography. Antivir Ther 2009; 14: 489–499.

Chan

H.L.

, Tsang

S.W.

, Liew

C.T.

Viral genotype and hepatitis B virus DNA levels are correlated with histological liver damage in HBeAg-negative chronic hepatitis B virus infection. Am J Gastroenterol 2002; 97: 406–412.

Sung

J.J.

, Chan

H.L.

, Wong

M.L.

Relationship of clinical and virological factors with hepatitis activity in hepatitis B e antigen-negative chronic hepatitis B virus-infected patients. J Viral Hepat 2002; 9: 229–234.

Chen

C.J.

, Yang

H.I.

, Su

Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006; 295: 65–73.

Chan

H.L.

, Tse

C.H.

, Mo

High viral load and hepatitis B virus subgenotype Ce are associated with increased risk of hepatocellular carcinoma. J Clin Oncol 2008; 26: 177–182.

Lok

A.S.

, McMahon

B.J.

Chronic hepatitis B. Hepatology 2007; 45: 507–539.

European Association for the Study of the Liver. EASL Clinical practice guidelines: management of chronic hepatitis B. J Hepatol 2009; 50: 227–242.

Liaw

Y.F.

, Leung

N.W.

, Kao

J.H.

Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update. Hepatol Int. 2008; 2: 263–283.

10.

Marcellin

, Bonino

, Lau

G.K.

Sustained response of hepatitis B e antigen-negative patients 3 years after treatment with peginterferon alfa-2a. Gastroenterology 2009; 136: 2169–2179.

11.

Marcellin

, Heathcote

E.J.

, Buti

Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. N Engl J Med 2008; 359: 2442–2455.

12.

Lai

C.L.

, Gane

, Liaw

Y.F.

Telbivudine versus lamivudine in patients with chronic hepatitis B. N Engl J Med 2007; 357: 2576–2588.

13.

Lai

C.L.

, Shouval

, Lok

A.S.

Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2006; 354: 1011–1020.

14.

Hadziyannis

S.J.

, Tassopoulos

N.C.

, Heathcote

Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years. Gastroenterology 2006; 131: 1743–1751.

15.

Gane

, Weilet

, Sievert

Three years efficacy and safety of tenofovir disoproxil fumarate (TDF) in Asians with HBeAg-positive and HBeAg-negative chronic hepatitis B, preliminary analysis. 20th Conference of the Asian Pacific Association for the Study of the Liver. 25–28 March, 2010, Beijing, China. Abstract FP-019.

16.

Hadziyannis

S.J.

, Sevastianos

, Rapti

I.N.

, Tassopoulos

Sustained biochemical and virological remission after discontinuation of 4 to 5 years of adefovir dipivoxil (ADV) treatment in HBeAg-negative chronic hepatitis B. 57th Annual meeting of The American Association for the Study of Liver Diseases. 27–31 October 2006, Boston, MA, USA. Abstract 114.

17.

Chan

H.L.

, Wang

, Niu

, Chim

A.M.

, Sung

J.J.

Two-year lamivudine treatment for hepatitis B e antigen-negative chronic hepatitis B: a double-blind, placebo-controlled trial. Antivir Ther 2007; 12: 345–353.

18.

Chan

H.L.

, Wong

V.W.

, Hui

A.Y.

Long term lamivudine treatment is associated with good maintained response in severe acute exacerbation of hepatitis B e antigen-negative chronic hepatitis B. Antivir Ther 2006; 11: 465–471.

19.

Werle-Lapostolle

, Bowden

, Locarnini

Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy. Gastroenterology 2004; 126: 1750–1758.

20.

Chan

H.L.

, Wong

V.W.

, Tse

A.M.

Serum hepatitis B surface antigen quantitation can reflect hepatitis B virus in the liver and predict treatment response. Clin Gastroenterol Hepatol 2007; 5: 1462–1468.

21.

Brunetto

M.R.

, Moriconi

, Bonino

Hepatitis B virus surface antigen levels: a guide to sustained response to peginterferon alfa-2a in HBeAg-negative chronic hepatitis B. Hepatology 2009; 49: 1141–1150.

22.

Rijckborst

, Hansen

B.E.

, Cakaloglu

Early on-treatment prediction of response to peginterferon alfa-2b for HBeAg-negative chronic hepatitis B using HbsAg and HBV DNA levels. Hepatology 2010; 52: 454–461.

23.

Wursthorn

, Jung

, Riva

Kinetics of hepatitis B surface antigen decline during 3 years of telbivudine treatment in hepatitis B e antigen-positive patients. Hepatology 2010; 52: 1611–1620.

24.

Liaw

Y.F.

, Sung

J.J.

, Chow

W.C.

Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 2004; 351: 1521–1531.

25.

Chan

H.L.

, Chui

A.K.

, Lau

W.Y.

Factors associated with viral breakthrough in lamivudine monoprophylaxis of hepatitis B virus recurrence after liver transplantation. J Med Virol 2002; 68: 182–187.

26.

Chan

H.L.

, Leung

N.W.

, Hussain

, Wong

M.L.

, Lok

A.S.

Hepatitis B e antigen-negative chronic hepatitis B in Hong Kong. Hepatology 2000; 31: 763–768.

27.

Cai

, Xie

, An

On-treatment serum HBsAg level is predictive of sustained off-treatment virological response to telbivudine in HBeAg-positive chronic hepatitis B patients. J Clin Virol 2010; 48: 22–26.

28.

Thompson

A.J.

, Nguyen

, Iser

Serum hepatitis B surface antigen and hepatitis B e antigen titers: Disease phase influences correlation with viral load and intrahepatic hepatitis virus markers. Hepatology 2010; 51: 1933–1944.

29.

Lin

L.Y.

, Wong

V.W.

, Zhou

H.J.

Relationship between serum hepatitis B virus DNA and surface antigen with covalently closed circular DNA in HBeAg-negative patients. J Med Virol 2010; 82: 1494–1500.

30.

Volz

, Lutgehetmann

, Wachtler

Impaired intrahepatic hepatitis B virus productivity contributes to low viremia in most HBeAg-negative patients. Gastroenterology 2007; 133: 843–852.

31.

Chan

H.L.

, Wong

V.W.

, Wong

G.L.

, Tse

C.H.

, Chan

H.Y.

, Sung

J.J.

A longitudinal study on the natural history of serum HBsAg changes in chronic hepatitis B. Hepatology 2010; 52: 1232–1241.

32.

Sung

J.J.

, Wong

M.L.

, Bowden

Intrahepatic hepatitis B virus covalently closed circular DNA can be a predictor of sustained response to therapy. Gastroenterology 2005; 128: 1890–1897.

33.

Manesis

E.K.

, Hadziyannis

E.S.

, Angelopoulou

O.P.

, Hadziyannis

S.J.

Prediction of treatment-related HBsAg loss in HBeAg-negative chronic hepatitis B: a clue from serum HBsAg levels. Antivir Ther 2007; 12: 73–82.

34.

Chan

H.L.

, Wong

V.W.

, Chim

A.M.

, Chan

H.Y.

, Wong

G.L.

, Sung

J.J.

Serum HBsAg quantification to predict response to peginterferon therapy of e antigen positive chronic hepatitis B. Aliment Pharmacol Ther 2010; 32: 1323–1331.

35.

Moucari

, Mackiewicz

, Lada

Early serum HBsAg drop: A strong predictor of sustained virological response to pegylated interferon alfa-2a in HBeAg-negative patients. Hepatology 2009; 49: 1151–1157.

36.

Wiegand

, Wedemeyer

, Finger

A decline in hepatitis B virus surface antigen (HBsAg) predicts clearance, but does not correlate with quantitative HBeAg or HBV DNA levels. Antivir Ther 2008; 13: 547–554.

37.

Wong

G.L.

, Chan

H.L.

Predictors of treatment response in chronic hepatitis B. Drugs 2009; 69: 2167–2177.